Loading...
Loading...
In a report published Tuesday, JMP Securities analyst John L. Newman initiated coverage on
LpathLPTN with a Market Outperform rating and $14.00 price target.
In the report, JMP Securities noted, “We are initiating coverage on Lpath with a Market Outperform rating and establishing a $14 price target based on a probability-adjusted Net Present Value calculation. Lpath is developing two lipid-targeting antibodies, iSONEP for eye disease, and ASONEP for kidney cancer, with iSONEP holding under-appreciated value, in our view.”
Lpath closed on Monday at $4.81.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in